Array Biopharma Inc
ARRY
ARRY was delisted on the 29th of July, 2019.
191 hedge funds and large institutions have $2.56B invested in Array Biopharma Inc in 2017 Q4 according to their latest regulatory filings, with 35 funds opening new positions, 75 increasing their positions, 57 reducing their positions, and 28 closing their positions.
96% more call options, than puts
Call options by funds: $44M | Put options by funds: $22.5M
75% more funds holding in top 10
Funds holding in top 10: 4 → 7 (+3)
32% more repeat investments, than reductions
Existing positions increased: 75 | Existing positions reduced: 57
25% more first-time investments, than exits
New positions opened: 35 | Existing positions closed: 28
6% more capital invested
Capital invested by funds: $2.41B → $2.56B (+$154M)
4% more funds holding
Funds holding: 184 → 191 (+7)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BI
BVF Inc
San Francisco,
California
|
+$26M |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
+$22M |
| 3 |
State Street
Boston,
Massachusetts
|
+$21.1M |
| 4 |
BlackRock
New York
|
+$19.4M |
| 5 |
EC
EcoR1 Capital
San Francisco,
California
|
+$18.6M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
O
OrbiMed
New York
|
-$74.6M |
| 2 |
Point72 Asset Management
Stamford,
Connecticut
|
-$37.5M |
| 3 |
PC
PointState Capital
New York
|
-$16.8M |
| 4 |
Citadel Advisors
Miami,
Florida
|
-$16.5M |
| 5 |
Two Sigma Investments
New York
|
-$13M |
ARRY Hedge Fund Activity: Q4 2017 in Review
191 of the 4,419 institutional investors tracked by Wall St. Rank reported a position in Array Biopharma Inc (ARRY) for Q4 2017, worth a combined $2.56B — up 6.4% from $2.41B a quarter earlier.
Buyers outnumbered sellers: 35 funds opened new ARRY positions and 28 closed out — a net gain of 7 holders — while 75 added to existing stakes and 57 trimmed.
The largest buyer was BVF Inc, adding an estimated $26M. The largest seller was OrbiMed, cutting an estimated $74.6M.
- 191 institutional investors held Array Biopharma Inc (ARRY) as of Q4 2017, up from 184 in Q3 2017.
- Funds reported $2.56B of Array Biopharma Inc stock for Q4 2017, up 6.4% quarter-over-quarter.
- 35 funds opened new Array Biopharma Inc positions in Q4 2017 and 28 closed out, a net change of +7 holders.
- The largest Array Biopharma Inc buyer in Q4 2017 was BVF Inc, an estimated $26M added.
- The largest Array Biopharma Inc seller in Q4 2017 was OrbiMed, an estimated $74.6M sold.
Based on aggregated 13F filings for Q4 2017.